Amicus Therapeutics Announces Second Quarter 2008 Financi...(t (8151) $- $...),Health

General and

administrative (3,959) (1,159) (5,118)

Depreciation and

amortization (332) (332)

Interest income 1,331 1,331

Interest expense (59) (59)

(Provision for)/benefit

from income taxes (75) (75)

Summary:

Net loss: $(7,438) $- $(1,856) $(9,294)

Net loss per share -

basic and diluted: $(0.33) $- $(0.08) $(0.41)

Weighted average

number

of shares

outstanding: 22,467,198 22,467,198

Table 3

Amicus Therapeutics, Inc.

Reconciliation of GAAP to non-GAAP Measures for the Statement of Operations Information for Three Months Ended June 30, 2007

(Unaudited)

(In thousands, except share and per share amounts)

Change in

Fair Value Preferred

Non- of Warrant Stock Stock GAAP as

GAAP Liability Accretion Compensation Reported

Income Statement

Classifications:

Research and

development $(6,361) $- $- $(422) $(6,783)

General and

administrative (2,607) (582) (3,189)

Depreciation and

amortization (312) (312)

Interest income 1,060 1,060

Interest expense (86) (86)

Change in fair

value of

warrant

liability -
'/>"/>